Skip to main content

Research Repository

Advanced Search

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence

Abdalla, Mohammed Altigani; Deshmukh, Harshal; Atkin, Stephen; Sathyapalan, Thozhukat

Authors

Mohammed Altigani Abdalla

Harshal Deshmukh

Stephen Atkin

Thozhukat Sathyapalan



Abstract

© The Author(s), 2021. Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. Metabolic consequences associated with PCOS include, but are not limited to, insulin resistance (IR), type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). This narrative review aims to provide a comprehensive overview of the potential therapeutic roles of the incretin-based therapies in the management of PCOS. Methods: We performed a systematic search of databases including PubMed, MEDLINE and EMBASE up to 1 October 2020. We developed a search string of medical subject headings (MeSH) including the terms PCOS, incretin mimetics, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 receptor antagonists (GLP-1 RAs), liraglutide, exenatide, semaglutide, dipeptidyl peptidase-4 (DPP-4) inhibitors, combined with IR, testosterone and sex hormone-binding globulin (SHBG). Results: We identified 854 relevant articles and, after the initial screening, eight interventional animal studies, one observational animal study, 14 interventional human studies, two case–control studies and one systematic review were included. These studies showed the potential significant roles of GLP-1 RAs and DPP-4 inhibitors in the management of PCOS, with significant improvements in the metabolic parameters, including substantial weight reduction and improved insulin sensitivity. These agents also improved the hormonal parameters through decreased free androgen and increased SHBG. Moreover, they improved menstrual regularity, increased fertility with enhanced ovulation and pregnancy in obese women with PCOS. Conclusion: GLP-1 RAs and DPP-4 inhibitors have a promising therapeutic role in PCOS; however, larger clinical trials are needed to establish the role of incretin-based therapies in the management of PCOS.

Citation

Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2021). The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Therapeutic Advances in Endocrinology and Metabolism, 12, https://doi.org/10.1177/2042018821989238

Journal Article Type Review
Acceptance Date Jan 3, 2021
Online Publication Date Jan 27, 2021
Publication Date Jan 27, 2021
Deposit Date May 15, 2021
Publicly Available Date May 17, 2021
Journal Therapeutic Advances in Endocrinology and Metabolism
Print ISSN 2042-0188
Electronic ISSN 2042-0196
Publisher SAGE Publications
Peer Reviewed Peer Reviewed
Volume 12
DOI https://doi.org/10.1177/2042018821989238
Public URL https://hull-repository.worktribe.com/output/3711050

Files

Published article (344 Kb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by-nc/4.0

Copyright Statement
© The Author(s), 2021.
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).



You might also like



Downloadable Citations